Skip to main content
. 2021 Nov 25;22(4):473–482. doi: 10.1016/S1473-3099(21)00680-0

Table 1.

Baseline characteristics of the participants included in vaccine effectiveness analyses

Cases (n=2766) Controls (n=2377)
Age, years 35 (28–45) 32 (26–42)
Sex
Male 1804 (65·2%) 1626 (68·4%)
Female 962 (34·8%) 751 (31·6%)
High risk of COVID-19 exposure at workplace 56 (2·0%) 60 (2·5%)
Duration between the two vaccine doses among vaccinated participants, days 33 (29–50; n=109) 31 (28–45; n=202)
Mild COVID-19 symptoms 2679 (96·5%) NA
Oxygen supplementation 89 (3·2%) NA
Admission to the intensive care unit 26 (0·9%) NA
Ventilatory support 7 (0·3%) NA
Death 16 (0·6%) NA

Data are median (IQR) or n (%). NA=not applicable.